摘要
Hepatitis C virus (HCV) infection and type 2 diabetes mellitus (T2DM) present a significant health burden,with increasing complications and mortality rates worldwide.Pycnogenol(R) (PYC),a natural product,possesses antidiabetic and antiviral properties that may improve HCV-associated T2DM.In this review,we present previously published data on the effectiveness of PYC against HCV replication and T2DM.We believe that supplementing conventional treatment with PYC may improve the current HCV therapy,attenuate HCV-associated T2DM,and reduce the risk of complications such as cirrhosis or hepatocellular carcinoma and cardiovascular disease.
Hepatitis C virus (HCV) infection and type 2 diabetes mellitus (T2DM) present a significant health burden,with increasing complications and mortality rates worldwide.Pycnogenol(R) (PYC),a natural product,possesses antidiabetic and antiviral properties that may improve HCV-associated T2DM.In this review,we present previously published data on the effectiveness of PYC against HCV replication and T2DM.We believe that supplementing conventional treatment with PYC may improve the current HCV therapy,attenuate HCV-associated T2DM,and reduce the risk of complications such as cirrhosis or hepatocellular carcinoma and cardiovascular disease.
基金
The study was supported by the Association de Lutte Contre le SIDA (ALCS,FASP 2013)
